



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

application of:

Erwin SI *et al.*

Group Art Unit: 1651

Appln. No.: 09/523,102

Examiner: S. Saucier

Filed: March 10, 2000

Atty. Docket: 13587.286

For: *Methods and Compositions for Treating and Preventing Retinal Neovascularization*

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


The attention of the Examiner is invited to the documents listed on the attached Form PTO-1449. Copies of the listed documents are submitted herewith.

It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

CERTIFICATION AND/OR FEE


Because this Information Disclosure Statement is being submitted prior to issuance of the first action on the merits of the above-captioned application, no certification or fee is required.

Respectfully submitted,


Joel M. Freed (Reg. No. 25,101)
Joseph W. Ricigliano (Reg. Agent No. 48,511)

Date: August 6, 2004

ARNOLD & PORTER LLP
555 Twelfth Street, N.W.
Washington, D.C. 20004-1206
(202) 942-5000 telephone
(202) 942-5999 facsimile



 FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO.:13587.286	APPLICATION NO.: 09/523,102
	Applicants: Erwin SI <i>et al.</i>	
	FILING DATE March 10, 2000	GROUP 1651

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.